- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06834373
Golcadomid a rituximab jako přemostění terapie pro relapsované nebo refrakterní agresivní agresivní B-buňka non-Hodgkinů před terapií automobilů
Fáze 2 Studie golcadomidu s rituximabem jako přemostění terapie před CAR-T u pacientů s relapsovaným nebo primárním refrakterním agresivním agresivním B-buněčným non-Hodgkinským lymfomem (NHL)
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Patients that are able to receive CAR T-cell therapy have a potential for cure, however, many will not be qualified to receive therapy due to relapse. Bridging therapy is therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy. Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide and rituximab as bridging therapy before CAR T-cell therapy may kill more tumor cells and may improve the chance of proceeding to CAR T-cell therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Přehled studie
Postavení
Podmínky
- Recidivující transformovaný non-Hodgkinův lymfom
- Recidivující difúzní velký B-buněčný lymfom, jinak nespecifikováno
- Refrakterní difuzní velký B-buněčný lymfom, jinak nespecifikováno
- Recidivující agresivní B-buněčný non-Hodgkinův lymfom
- Refrakterní agresivní B-buněčný non-Hodgkinův lymfom
- Typ rekurentního difúzního velkého B-lymfocytárního lymfomu s aktivovaným B-buňkou
- Refrakterní difuzní typ B-buněk aktivovaný velkým B-lymfomem
- Recidivující folikulární lymfom stupně 3b
- Refrakterní folikulární lymfom 3b. stupně
- Refrakterní transformovaný non-Hodgkinův lymfom
- Velký B-buněčný lymfom s přeskupením IRF4
- Recidivující intravaskulární velký B-buněčný lymfom
- Recidivující velký B-buněčný lymfom bohatý na T-buňky/histiocyty
- Refrakterní intravaskulární velký B-buněčný lymfom
- Refrakterní velký B-buněčný lymfom bohatý na T-buňky/histiocyty
- Recidivující primární kožní difúzní velký B-buněčný lymfom, typ nohy
- Refrakterní primární kožní difúzní velký B-buněčný lymfom, typ nohy
- Recidivující difúzní velkobuněčný B-lymfom spojený s chronickým zánětem
- Recidivující EBV-pozitivní difuzní velký B-buněčný lymfom, jinak nespecifikováno
- Recidivující B-buněčný lymfom vysokého stupně, jinak nespecifikovaný
- Refrakterní difúzní velký B-buněčný lymfom spojený s chronickým zánětem
- Refrakterní EBV-pozitivní difuzní velký B-buněčný lymfom, jinak nespecifikováno
- Refrakterní B-buněčný lymfom vysokého stupně, jinak nespecifikováno
- Recidivující difúzní velký B-buněčný lymfom Germinální centrum typu B-buněk
- Refrakterní difúzní velký B-buněčný lymfom Germinální centrum typu B-buněk
- Recidivující primární mediastinální velký B-buněčný lymfom
- Refrakterní primární mediastinální velký B-buněčný lymfom
- Opakující se ALK-pozitivní velký lymfom B-buněk
- Opakující se lymfom B-buněk s vysokým stupněm s MYC a Bcl2 přeskupením
- Refrakterní ALK-pozitivní velký lymfom B-buněk
- Refrakterní lymfom B-buněk s vysokým stupněm s MYC a Bcl2 přeskupením
Detailní popis
PRIMARY OBJECTIVE:
I. Evaluate efficacy as measured by the disease control rate (complete metabolic response [CMR], partial metabolic response [PMR], and no metabolic response [NMR]) by Lugano 2014 positron emission tomography (PET)-computed tomography (CT) based assessment after 2 cycles of therapy.
SECONDARY OBJECTIVES:
I. To further evaluate clinical efficacy as measured by overall response rate (ORR), complete response (CMR) rate, disease control rate by Lugano PET-CT based criteria.
II. To evaluate the safety and tolerability of golcadomide + rituximab combination therapy as measured by the incidence and severity of treatment related adverse events (TRAE).
III. To evaluate efficacy as a bridging therapy as measured by the number of patients proceeding to CAR-T and response to CAR-T.
IV. To evaluate duration of response, progression-free survival, and overall survival.
EXPLORATORY OBJECTIVES:
I. Improvement of symptoms (compressive, pain, B symptoms [fever, night sweats, weight loss]) associated with the disease as determined by the investigator.
II. To evaluate the diversity of CAR-T products received in patients proceeding to CAR-T.
OUTLINE:
ELIGIBLE FOR CAR-T: Patients receive golcadomide orally (PO) once daily (QD) on days 1-14 of each cycle and rituximab intravenously (IV) on days 1, 8, 15 and 22 of cycle 1 and then on day 1 of all subsequent cycles. Cycles repeat every 28 days for up to 1 cycle in the absence of disease progression or unacceptable toxicity. After 1 cycle, patients undergo leukapheresis and receive an additional cycle of golcadomide and rituximab (bridging therapy) prior to undergoing standard of care CAR-T therapy. Patients may also receive optional bridging therapy with golcadomide and rituximab per physician choice (1-2 cycles) prior to undergoing standard of care CAR-T therapy.
INELIGIBLE FOR CAR-T: Patients receive golcadomide PO QD on days 1-14 of each cycle and rituximab IV on days 1, 8, 15 and 22 of cycle 1 and then on day 1 of all subsequent cycles. Patients eligible for CAR-T after 2 cycles receive additional bridging therapy and undergo leukapheresis. Patients ineligible for CAR-T after 2 cycles, receive golcadomide PO QD on days 1-14 of each cycle and rituximab IV on day 1 of each cycle. Cycles repeat every 28 days for 3 cycles (cycles 3-5) in the absence of disease progression or unacceptable toxicity. Patients eligible for CAR-T after 5 cycles receive additional bridging therapy and undergo leukapheresis. Patients ineligible for CAR-T after 5 cycles, receive golcadomide PO QD on days 1-14 of each cycle. Cycles repeat every 28 days for 6 cycles (cycles 6-12) in the absence of disease progression or unacceptable toxicity.
Patients also undergo blood sample collection and PET/CT or CT throughout the study. Additionally, patients may undergo bone marrow aspiration and biopsy as clinically indicated.
CAR-T ineligible patients are followed up at 28 days and then every 3 months for 1 year from end of treatment until progression of disease, death, or initiation of new systemic anticancer therapies. CAR-T eligible patients are followed up at 30 and 90 days post CAR-T therapy, 180 days post CAR-T therapy, and then every 6 months until progression or subsequent treatment for up to 2 years
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní kontakt
- Jméno: Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
Studijní místa
-
-
Arizona
-
Scottsdale, Arizona, Spojené státy, 85259
- Nábor
- Mayo Clinic in Arizona
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Vrchní vyšetřovatel:
- Javier L. Munoz, MD, MBA
-
-
Florida
-
Jacksonville, Florida, Spojené státy, 32224-9980
- Nábor
- Mayo Clinic in Florida
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Vrchní vyšetřovatel:
- Muhamad Alhaj Moustafa, MD, MS
-
-
Minnesota
-
Albert Lea, Minnesota, Spojené státy, 56007
- Nábor
- Mayo Clinic Health System in Albert Lea
-
Vrchní vyšetřovatel:
- Mina Hanna, MD
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Mankato, Minnesota, Spojené státy, 56001
- Nábor
- Mayo Clinic Health Systems-Mankato
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Vrchní vyšetřovatel:
- Amrit B. Singh, MBBS
-
Rochester, Minnesota, Spojené státy, 55905
- Nábor
- Mayo Clinic in Rochester
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Vrchní vyšetřovatel:
- Claire Tiger, MD, PhD
-
-
Wisconsin
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Nábor
- Mayo Clinic Health System-Eau Claire Clinic
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Vrchní vyšetřovatel:
- Eyad S. Al-Hattab, MD
-
La Crosse, Wisconsin, Spojené státy, 54601
- Nábor
- Mayo Clinic Health System-Franciscan Healthcare
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Vrchní vyšetřovatel:
- Scott H. Okuno, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Age ≥ 18 years
-
Confirmed pathology diagnosis according to 2016 World Health Organization (WHO) classification including patients with diseases listed below with relapsed, progressive and/or refractory disease (Cheson et al. 2014) following treatment with one or two prior lines of standard therapy, no more than two lines of therapy are permitted:
-
Diffuse large B-cell lymphoma not otherwise specified (NOS) including:
- Transformed lymphoma
- Germinal center B-cell type
- Activated B-cell type
-
High-grade B-cell lymphoma (HGBCL), NOS
-
High grade B-cell lymphoma with MYC and BCL2 translocation
-
Primary mediastinal (thymic) large B-cell lymphoma
-
Grade 3B follicular lymphoma
-
T-cell/histiocyte-rich large B-cell lymphoma
-
Large B-cell lymphoma with IRF4 rearrangement
-
Primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type
-
Epstein-Barr virus (EBV) positive DLBCL, NOS
-
DLBCL associated with chronic inflammation
-
Intravascular large B-cell lymphoma
-
ALK positive large B-cell lymphoma
-
NOTE: Richters transformation patients are excluded
-
-
Measurable disease by PET-CT with at least one lymph node or other type of lesion that has a size > 1.5 cm in the transverse diameter, as defined by Lugano classification
- NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible
-
Patient is potentially eligible for CAR-T therapy as determined by treating physician
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
-
Hemoglobin > 7.0 g/dL (obtained ≤ 14 days prior to registration)
-
Absolute neutrophil count (ANC) ≥ 1000/mcL (obtained ≤ 14 days prior to registration); growth factor support allowed at physician discretion
-
Platelet count ≥ 75,000/mcL (obtained ≤ 14 days prior to registration)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration); if total bilirubin is > 1.5 ULN, direct bilirubin must be normal
-
Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)
-
Estimated Glomerular function (eGFR) of >= 30 mL/min/1.73m^2 using the Cockcroft-Gaultmodification of diet in renal disease (MDRD) formula or Chronic Kidney Disease - Epidemiology Collaboration formula (CKD-EPI). CKD-EPI can be calculated either using creatinine or cystatin C. The same eGFR cutoff applies in case of documented renal involvement by lymphoma (obtained ≤ 14 days prior to registration)
-
Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282:
- A negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at screening (between 10 to 14 days prior to cycle 1 day 1)
- A negative serum or urine pregnancy test (investigator's discretion) within 24 hours prior to cycle 1 day 1 of study treatment
-
Provide written informed consent
-
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
-
Subjects must agree not to donate blood while receiving golcadomide, during dose interruptions and for ≥ 28 days following the last dose of golcadomide
Exclusion Criteria:
-
Any of the following because this study involves an investigational agent that has known genotoxic, mutagenic, and teratogenic effects:
- Pregnant persons
- Nursing persons
-
Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception
-
Persons of childbearing potential (PCBP) unwilling to use two reliable forms of contraception simultaneously or to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal or postovulation methods] and withdrawal are not acceptable methods of contraception) from heterosexual contact during the following time periods related to this study:
-
For ≥ 28 days before starting treatment, during treatment and dose interruptions, and for ≥ 28 days after the last dose of golcadomide
-
Examples of highly effective methods of contraception:
- Intrauterine device (IUD)
- Hormonal (birth control pills, injections, implants, levonorgestrel-releasing intrauterine system [IUS], medroxyprogesterone acetate depot injections, ovulation inhibitory
- Progesterone-only pills [e.g., desogestrel])
- Tubal ligation
- Partner's vasectomy
-
Examples of additional effective methods:
- Male condom
- Diaphragm
- Cervical cap
-
Persons who can father a child unwilling to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal or post-ovulation methods] and withdrawal are not acceptable methods of contraception.) or unwilling to use a condom during sexual contact with a pregnant person or a PCBP during treatment and dose interruptions, and for > 28 days following the last dose of golcadomide, even if they have undergone a successful vasectomy
-
Persons who can father a child and are unwilling to refrain from donating semen or sperm while receiving golcadomide, during dose interruptions, or for ≥ 28 days following the last dose of golcadomide
-
-
Life expectancy < 3 months
-
Any of the following prior therapies:
-
Any prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to registration
-
Any prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to registration, whichever is shorter
- Exception: Monoclonal and bispecific antibodies is acceptable
-
Prior therapy with golcadomide ≤ 4 weeks prior to registration
-
Prior autologous stem cell transplantation (SCT) ≤ 3 months prior to registration. If subject had autologous SCT > 3 months prior to the start of registration, any treatment-related toxicity is unresolved (grade > 1)
-
Major surgery ≤ 3 weeks prior to registration
-
Chemotherapy ≤ 2 weeks prior to registration
-
Concomitant radiation therapy; local palliative radiotherapy is permitted
-
-
Co-morbid systemic illnesses or other severe concurrent disease or cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
-
Impaired cardiac function or clinically significant cardiac diseases including, but not limited to:
- Symptomatic congestive heart failure
- History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
- Unstable angina pectoris
- Cardiac arrhythmia
-
Uncontrolled intercurrent non-cardiac illness including, but not limited to:
- Ongoing or active infection
- Psychiatric illness/social situations
- Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy (such as interstitial lung disease or chronic obstructive pulmonary disease [COPD])
- Any other conditions that would limit compliance with study requirements
-
Subject had prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration. If subject had prior allogeneic SCT > 6 months prior to registration, any treatment-related toxicity is unresolved (grade >1)
-
Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy, as there is currently no safety data in HIV positive patients
-
Subject has known chronic active hepatitis B or C virus (HBV/HCV) infection
- Exception: Patients with HBV and an undetectable viral load who are on suppressive therapy and/or those with HCV and an undetectable viral load are allowed
-
Concurrent administration of strong or moderate CYP3A4/5 inhibitors and inducers within 14 days or 5 half-lives, whichever is longer before the study treatment administration
-
Receiving any other investigational agent which would be considered as a treatment for lymphoma.
- Exception: Corticosteroids are allowed
-
Active second malignancy requiring treatment that would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy
-
History of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia. Patients with a history of deep vein thrombosis (DVT)/pulmonary embolism (PE) or thrombophilia may still participate if they are willing to be on full anticoagulation during treatment. Full anticoagulation is defined as Warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses. The rationale for this requirement is that golcadomide therapy is associated with an increased risk of thrombosis. Patients with no history of DVT/PE or thrombophilia are not required to take anticoagulation and/or anti-platelet prophylaxis
- NOTE: If a patient develops a thrombotic event, they must be able and willing to receive anticoagulation therapy with aspirin 81-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or Warfarin. This is due to an increased risk of thrombosis in patients treated with golcadomide without prophylaxis
-
Live COVID-19 vaccine administered ≤ 28 days prior to registration
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Treatment (golcadomide, rituximab)
ELIGIBLE FOR CAR-T: Patients receive golcadomide orally (PO) once daily (QD) on days 1-14 of each cycle and rituximab intravenously (IV) on days 1, 8, 15 and 22 of cycle 1 and then on day 1 of all subsequent cycles. After 1 cycle, patients undergo leukapheresis and receive an additional cycle of golcadomide and rituximab (bridging therapy) prior to undergoing standard of care CAR-T therapy. Patients may also receive optional bridging therapy with golcadomide and rituximab per physician choice (1-2 cycles) prior to undergoing standard of care CAR-T therapy. INELIGIBLE FOR CAR-T: Patients receive golcadomide PO QD on days 1-14 of each cycle and rituximab IV on days 1, 8, 15 and 22 of cycle 1 and then on day 1 of all subsequent cycles. Patients receive golcadomide PO QD on days 1-14 of each cycle and rituximab IV on day 1 of each cycle. Patients ineligible for CAR-T after 5 cycles, receive golcadomide PO QD on days 1-14 of each cycle. See Detailed Description for more info. |
Undergo blood sample collection
Ostatní jména:
Given IV
Ostatní jména:
Undergo bone marrow aspiration and biopsy Undergo bone marrow aspiration and biopsy
Ostatní jména:
Undergo CT or PET/CT
Ostatní jména:
Undergo PET/CT
Ostatní jména:
Undergo leukapheresis
Ostatní jména:
Undergo standard of care CAR-T therapy
Ostatní jména:
Given PO
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Disease control
Časové okno: 2 cycles (cycle length = 28 days)
|
Will be defined as a complete metabolic response (CMR), partial metabolic response (PMR), or no metabolic response (NMR) by Lugano 2014 PET-CT. |
2 cycles (cycle length = 28 days)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Disease control rate
Časové okno: Up to 2 years
|
Will be estimated by the total number of patients who achieve a CMR, PMR, or NMR by Lugano 2014 positron emission tomography (PET)/computed tomography (CT) divided by the total number of evaluable patients. |
Up to 2 years
|
|
Complete response rate
Časové okno: Up to 2 years
|
Will be assessed by the total number of patients who achieve a CMR by Lugano 2014 PET/CT. |
Up to 2 years
|
|
Overall response rate
Časové okno: Up to 2 years
|
Will be assessed by the total number of patients who achieve a CMR or PMR by Lugano 2014 PET/CT divided. |
Up to 2 years
|
|
The proportion of patients proceeding to chimeric antigen receptor T-cell (CART)
Časové okno: Up to 2 years
|
Will be assessed by the total number of patients who proceed to CART divided by the total number of evaluable patients. |
Up to 2 years
|
|
Overall response rate to CART
Časové okno: Up to 2 years
|
Will be assessed by the total number of patients who achieve a CMR or PMR by Lugano 2014 PET/CT after CART. |
Up to 2 years
|
|
Duration of response
Časové okno: Up to 2 years
|
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CMR or PMR to first documentation of disease progression. |
Up to 2 years
|
|
Progression-free survival (PFS)
Časové okno: Up to 2 years
|
Progression-free survival is defined as the time from registration to first documentation of disease progression (PMD or PD) or death due to any cause in the absence of documented progression |
Up to 2 years
|
|
Overall survival (OS)
Časové okno: From registration to death due to any cause, assessed up to 2 years
|
Overall survival is defined as the time from registration to death due to any cause. |
From registration to death due to any cause, assessed up to 2 years
|
|
Incidence of adverse events (AEs)
Časové okno: Up to 30 days after last dose of study treatment
|
Will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE). The maximum grade for each type of AE will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the AE(s) to the study treatment will be taken into consideration and treatment related AEs will be evaluated. |
Up to 30 days after last dose of study treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Claire Tiger, MD, PhD, Mayo Clinic
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary
- Onemocnění imunitního systému
- Novotvary podle histologického typu
- Lymfatická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Lymfom, Non-Hodgkin
- Lymfom, B-buňka
- Lymfom
- Hemická a lymfatická onemocnění
- Lymfom, velký B-buňka, difuzní
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Vyšetřovací techniky
- Terapeutika
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Chirurgické postupy, operativní
- Cytologické techniky
- Cytodiagnosis
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Diagnostické techniky, chirurgické
- Techniky chemie, analytické
- Analýza spektra
- Protilátky, monoklonální, omyl odvozený
- Biologická terapie
- Cytaferéze
- Odstraňování složek krve
- Postupy redukce leukocytů
- Separace buněk
- Imunologické techniky
- Imunomodulace
- Adoptivní převod
- Imunizace, pasivní
- Imunizace
- Imunoterapie
- Rituximab
- Biopsie
- Manipulace se vzorkem
- Magnetická rezonanční spektroskopie
- Leukapheresis
- CT-P10
- Imunoterapie, adoptivní
Další identifikační čísla studie
- MC230813
- 24-005122 (Jiný identifikátor: Mayo Clinic Institutional Review Board)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .